Skeletal muscle is a privileged target for long-term rAAVmediated gene transfer in mouse, rat, dog and non-human primates. Intramuscular injections of rAAV encoding human factor IX in hemophilia B patients have been initiated, based on promising results gathered in affected dogs. We found that intramuscular rAAV administration in rats resulted in restricted transduction essentially along the myofibers axis with poor lateral diffusion. This suggested that the transduction rate might be limited by the ability of the virus to reach sites distant from the injection point. We tested whether hyaluronidase, an enzyme which dissociates the extracellular matrix, could enhance vector diffusion when injected in the rat muscle before administration of rAAV encoding either nuclear-localized ␤-galactosidase (rAAVCMVnlsLacZ) or the human ␣-1-antitrypsin (rAAVCMVhAAT) under the control of the cytomegalovirus immediate-early promoter (CMV). The Keywords: skeletal muscle; recombinant adeno-associated virus; hyaluronidase Recombinant adeno-associated viral vectors (rAAV) have emerged as an attractive alternative to retroviral and adenoviral vectors to transduce nondividing cells in vivo.
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Recombinant adeno-associated viral vectors (rAAV) have emerged as an attractive alternative to retroviral and adenoviral vectors to transduce nondividing cells in vivo. 1 Recombinant AAV vectors are derived from the 'wildtype' virus by deleting the rep and cap genes and replacing them with the transgene and transcription control elements. Usually, rAAV stocks are purified from 293 cells which are cotransfected with the AAV vector and a rep-cap expressing plasmid and subsequently infected with helper adenovirus. Alternatively, the adenoviral helper functions required for the production of rAAV can be provided by a nonreplicative plasmid resulting in rAAV stocks free of detectable adenovirus. 2 Despite the broad host range of rAAV in vitro, three preferential targets have been identified in vivo: the retina, skeletal muscle, and the central nervous system, where rAAV efficiently transduced post-mitotic and differentiated cells such as photoreceptors, myofibers and neurons. [3] [4] [5] Skeletal muscle is an easily accessible target for gene delivery and is highly vascularized. Efficient rAAV transduction of myofibers can be used to achieve the sustained in situ expression of reporter genes or the results showed that pretreatment of the rat anterior tibialis muscle with hyaluronidase resulted in: (1) a larger diffusion of the virus indicated by an increase in the area containing LacZ-transduced fibers, and (2) a two-to three-fold increase of transduction efficiency measured by the number of LacZpositive fibers or by the hAAT serum concentration. We also provide evidence that hyaluronidase was well tolerated and was not associated with short-or long-term toxicity evaluated by morphological studies. Finally, in our experimental conditions, hyaluronidase did not promote rAAV dissemination to other organs as assessed by PCR to detect vector sequences. We conclude that pretreament of skeletal muscle by hyaluronidase, a clinically available reagent, was harmless and resulted in a consistent and significant increase in rAAV diffusion and transduction levels. Gene Therapy (2000) 7, 1417-1420.
systemic delivery into the circulation of therapeutic proteins. The mouse has been used most commonly for rAAV evaluation in vivo and the anterior tibialis muscle remains the preferred site of vector administration. The small size of the target combined with large volumes of injected rAAV (30-100 l) allow diffuse transduction of the muscle reaching up to 40% of myofibers. 6, 7 In the present study rAAV-mediated transduction of the rat anterior tibialis muscle was analyzed. Intramuscular injection of rAAVCMVnlsLacZ into 250 g Wistar rats resulted in transduction essentially along the axis of myofibers with little lateral diffusion (data not shown). On average, 1% myofibers were routinely transduced using 7.8 × 10 9 rAAVCMVnlsLacZ particles (2.5 × 10 7 transducing particles as measured by LacZ staining of adenovirus co-infected 293 cells) in a total volume of 250 l saline, injected perpendicularly at three different sites at equal distances along the longitudinal axis. Increasing the total volume of injection to 500 l did not improve the level of transduction, nor did the longitudinal administration of the rAAV vector (data not shown). Actually, increasing the volume above 250 l resulted in obvious leakage outside the muscle despite making a cutaneous incision and exposing the muscle before rAAV injection. Overall, these observations indicated that rAAV had a restricted capacity to diffuse from the injection site and suggested that the confined diffusion of the vector was limiting the transduction rate of muscle fibers.
Gene Therapy
To improve rAAV diffusion and transduction we tested the effect of injecting hylauronidase into the muscle before rAAV administration. Hyaluronidase (Choay, Sanofi, France), is a mucolytic enzyme involved in the depolymerization and hydrolysis of hyaluronic acid, a major constituent of the extracellular matrix. One hundred units of the enzyme in 250 l saline were injected into the muscle of 12 rats 3 h before the administration of 2.5 × 10 7 rAAVnlsLacZ transducing particles (group B). The control group (group A) contained 12 animals receiving 250 l of saline instead of hyaluronidase and, 3 h later, the same dose of rAAVCMVnlsLacZ particles as group B. Four weeks later, the animals were killed and muscles were excised, paraformaldehyde-fixed and stained with X-gal to detect ␤-galactosidase activity. The results presented in Figure 1 indicate that pretreatment of the skeletal muscle with hyaluronidase increased rAAV diffusion compared with untreated muscle. To determine if hyaluronidase treatment also affected the rAAV trans- 6 duction rate, the number of ␤-galactosidase-expressing myofibers was counted for each animal in both groups (Figure 2 ). The number of positive fibers was found, on average, to be two-fold higher in hyaluronidase-treated animals than in the mock-injected controls (231 ± 118.3 versus 114.9 ± 61.7, respectively). Altogether, these data indicate that pretreament of skeletal muscle with hyaluronidase improved the diffusion of the rAAV vector in the tissue and resulted in a two-fold increase in the transduction events.
To validate this observation further, this protocol was repeated using an rAAV vector harboring the human ␣-1-antitrypsin (rAAVCMVhAAT) cDNA under the control of the CMV promoter. The hAAT protein can be expressed and secreted from myofibers and subsequently measured by ELISA in the serum. 8 This feature made the hAAT an appropriate marker gene to test the impact of hyaluronidase pretreatment on rAAV transduction. Six rats received 100 U of the enzyme intramuscularly, 3 h before the injection of 7.5 × 10 9 particles (1 × 10 8 infectious particles as measured by mRCA 9 ) of rAAVCMVhAAT vector (group B). Animals from the control group (group A, n = 6) were mock-treated with saline and subsequently injected with the same amount of rAACMVVhAAT vector as in group B. Nine weeks after vector administration, the circulating level of hAAT was approximately threefold higher in the hyaluronidase-treated animals than in sera from the control group (340 ± 130 pg/ml versus 120 ± 150 pg/ml, respectively) ( Figure 3 ). The same difference was found 20 weeks after injection indicating the persistance in both groups of the transduced myofibers ( Figure 3 ). The level of hAAT measured in these experiments was lower than the values recently reported by Song et al, 8 who injected into mice an rAAV encoding the human ␣-antitrypsin under the control of the CMV promoter. As in the experiments using the LacZ reporter gene, the low level of transduction observed might be due to the doses of rAAV injected and/or to a lower affinity of rAAV to rat muscle cells. Overall, our results confirmed that pretreatment of skeletal muscle with hyaluronidase improves transduction levels, in agreement with the data reported above using rAAVCMVnlsLacZ.
The short-term toxicity of hyaluronidase was studied on two rats killed 3 h after injection of 100 U of the enzyme. Hematoxylin and eosin staining carried out on parafin-embedded muscle tissue sections revealed histology that was indistinguishable from saline-injected rats (data not shown). Similarly, Jones's staining of the basement membrane indicated that hyaluronidase did not affect the muscle structure. Long-term toxicity studies performed on animals injected with hyaluronidase and killed 3 months later showed the same result (data not shown).
The last important issue related to hyaluronidase enhancement of rAAV diffusion and transduction in vivo concerned the possibility that the enzyme was also favoring rAAV spreading to other tissues, particularly the gonads. To investigate this possibility, the presence of Gene Therapy rAAVCMVhAAT DNA was searched by PCR analysis performed on total DNA extracted from different organs of animals killed 20 weeks after rAAVCMVhAAT injection ( Figure 4) . As expected, a positive signal was detected in DNA from the injected anterior tibialis muscle. More interestingly, no signal was detected in other organs including the liver and the gonads. Of course, systemic spread of the rAAV vector cannot be excluded when the volume and the vector concentration are increased. Viral dissemination of rAAV in non-human primates using hyaluronidase in a similar intra-muscular injection protocol is currently being evaluated.
Figure 4 Evaluation of rAAVhAAT vector spreading 20 weeks after vector administration. Total DNA was extracted from each indicated organ. The presence of vector DNA was searched for by PCR using a primer hybridizing in the CMV promoter (5Ј-ACATCAATGGGCGTGGAT-AGCGG-3Ј) and a second one hybridizing to the hAAT cDNA (5Ј-TGTCTGGCTGGTTTAGGGTACGG-3Ј
In conclusion, administration of hyaluronidase in skeletal muscle of rats before rAAV vector injection was demonstrated to increase the intramuscular diffusion of the viral vector and also to enhance the transduction level two-to three-fold. The enzyme had no short-or longterm toxicity on myofiber histology over a 3 month period. The fact that in vitro transduction of Hela cells with rAAVnlsLacZ was not modified by preincubation with hyaluronidase (data not shown), suggests that the enzyme may not act at the cellular level (for example by enhancing AAV entry into the cells) but rather through extracellular matrix dissociation enhancing vector diffusion in the tissue. Although Fromes et al 10 recently reported that hyaluronidase alone was ineffective in facilitating adenovirus-mediated gene transfer to the myocardium across the pericardial barrier, a mix of collagenase and hyaluronidase was found to enhance the diffusion of the recombinant adenovirus. Altogether, these observations indicate that hyaluronidase treatment may be important to enhance rAAV muscle diffusion and transduction in larger animals, such as non-human primates in which transduction rates are limited by the avaibility of high-titer rAAV.
